Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia
| Autor: | Sebastian Scholl, Claudia Krause, Ivan F. Loncarevic, K. Höffken, Christa Kunert, Joachim H. Clement |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Pediatrics Neoplasm Residual Internal tandem duplication Disease medicine.disease_cause Bone Marrow Recurrence Gene Duplication Proto-Oncogene Proteins hemic and lymphatic diseases Internal medicine medicine Humans Retrospective Studies Mutation Potential impact business.industry Receptor Protein-Tyrosine Kinases Myeloid leukemia Hematology Middle Aged Patient specific Minimal residual disease body regions Leukemia Myeloid Acute Treatment Outcome fms-Like Tyrosine Kinase 3 Karyotyping Female business Flt3 itd |
| Zdroj: | Leukemia Research. 29:849-853 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2004.12.001 |
| Popis: | We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In five out of six patients with a positive Flt3-ITD based MRD status a relapse of AML was observed in the follow up while one patient lacks a clinical relapse so far. In contrast, four out of five patients with a negative MRD status remain free of disease. One of these patients relapsed with a switch of FAB subtype including loss of Flt3-ITD mutation. Furthermore, in one patient we could identify a Flt3-ITT (internal tandem triplication mutation). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect